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Abstract
Aims/hypothesis Insoluble cereal fibres have been shown in large prospective cohort studies to be highly effective in preventing
type 2 diabetes, but there is a lack of interventional data. Our 2 year randomised double-blind prospective intervention study
compared the effect of an insoluble oat fibre extract with that of placebo on glucose metabolism and incidence of diabetes.
Methods A total of 180 participants with impaired glucose tolerance underwent a modified version of the 1 year lifestyle
training programme PREvention of DIAbetes Self-management (PREDIAS) and were randomised to receive a fibre
supplement (n = 89; 7.5 g of insoluble fibre per serving) or placebo (n = 91; 0.8 g of insoluble fibre per serving) twice
daily for 2 years. Eligible participants were men and women, were at least 18 years old and did not report corticosteroid or
other intensive anti-inflammatory treatment, fibre intolerance or any of the following disorders: overt diabetes, chronic or
malignant disease, or severe cardiopulmonary, endocrine, psychiatric, gastrointestinal, autoimmune or eating disorder.
Participants were recruited at two clinical wards in Berlin and Nuthetal. The allocation was blinded to participants and
study caregivers (physicians, dietitians, study nurses). Randomisation was conducted by non-clinical staff, providing
neutrally numbered supplement tins. Both supplements were similar in their visual, olfactory and gustatory appearance.
Intention-to-treat analysis was applied to all individuals.
Results After 1 year, 2 h OGTT levels decreased significantly in both groups but without a significant difference between the
groups (fibre −0.78 ± 1.88 mmol/l [p ≤ 0.001] vs placebo −0.46 ± 1.80 mmol/l [p = 0.020]; total difference 0.32 ± 0.29 mmol/l;
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not significant). The 2 year incidence of diabetes was 9/89 (fibre group) compared with 16/91 (placebo group; difference
not significant). As secondary outcomes, the change in HbA1c level was significantly different between the two groups
(−0.2 ± 4.6 mmol/mol [−0.0 ± 0.0%; not significant] vs +1.2 ± 5.2 mmol/mol [+0.1 ± 0.0%; not significant]; total differ-
ence 1.4 ± 0.7 mmol/mol [0.1 + 0.0%]); p = 0.018); insulin sensitivity and hepatic insulin clearance increased in both
groups. After 2 years, improved insulin sensitivity was still present in both groups, although the effect size had diminished.
Separate analysis of the sexes revealed a significantly greater reduction in 2 h glucose levels for women in the fibre group
(−0.88 ± 1.59 mmol/l [p ≤ 0.001] vs −0.22 ± 1.52 mmol/l [p = 0.311]; total difference 0.67 ± 0.31 mmol/l; p = 0.015).
Levels of fasting glucose, adipokines and inflammatory markers remained unchanged in the two groups. Significantly
increased fibre intake was restricted to the fibre group, despite dietary counselling for both groups. No severe side effects
occurred.
Conclusions/interpretation We cannot currently provide strong evidence for a beneficial effect of insoluble cereal fibre on
glycaemic metabolism, although further studies may support minor effects of fibre supplementation in reducing glucose levels,
insulin resistance and the incidence of type 2 diabetes.
Trial registration: clinicaltrials.gov NCT01681173
Funding: German Diabetes Foundation (grant no. 232/11/08)
Keywords Cellulose .Diabetesmellitus type2 .Hemicellulose .Hepatic insulinclearance . Impairedglucose tolerance . Insoluble
dietary fibre . Insulin sensitivity . Prediabetes
Abbreviations
BIA Bioelectrical impedance analysis
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HIC Hepatic insulin clearance
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OptiFiT Optimal Fibre Trial for Diabetes Prevention
PREDIAS PREvention of DIAbetes Self-management
Sg Glucose effectiveness index
Introduction
The effectiveness of preventing type 2 diabetes mellitus
by moderate alterations in lifestyle has been proven in two
previous trials [1, 2]. Additionally, large epidemiological
studies have identified dietary fibre as one of the most
effective nutrient components for diabetes prevention








levels in most countries that consume Western-style foods
[4]. According to epidemiological data, the preventive ef-
fect of fibres is most evident with cereal but not at all with
fruit, legumes and vegetable fibres [5, 6]. Cereals contain
predominantly insoluble fibres from the coat region and a
smaller fraction of soluble fibres from the endosperm and
aleurone layers of the grain. The insoluble fraction is
composed of cellulose, hemicelluloses and lignin, and is
only modestly fermented, such that the greater part is
excreted with the faeces [7]. This modest fermentation
leads to little gas production in the intestine, making in-
soluble fibres more acceptable to people who are sensitive
to bowel symptoms.
Mechanisms linking insoluble fibres to glucose homeosta-
sis in humans point to a rapid, overnight improvement in
meal-related insulin sensitivity without significant changes
in insulin secretion when using either insoluble fermentable
or non-fermentable fibres or whole grain [8, 9]. Using cereal
fibre extracts identical to those used in the current study, we
have shown an improvemen t i n eug lycaemic–
hyperinsulinaemic-clamp-measured whole-body insulin sen-
sitivity after 3 days and 6 weeks in humans [10, 11], as well
as beneficial metabolic effects in a long-term controlled study
in C57BL/6J mice [7].
Long-term prospective randomised data on fibre sup-
plementation in humans are sparse, and available data do
not show striking changes in glycaemic variables. A 1 year
study involving 14 participants failed to demonstrate ben-
eficial effects, possibly due to relatively small differences
in fibre intake [12]. So far, no evidence for an interven-
tional effect of soluble fibre on glucose levels has been
provided [13–15].
Recent diabetes prevention trials have shown that life-
style intervention reduces the risk of incident diabetes by
40–60% compared with placebo [1, 2, 16, 17]. These
studies targeted primarily weight loss and increased phys-
ical activity. Other studies have investigated the effect of a
reduced intake of saturated and total fat and increased
fibre intake as part of daily nutrition. However, relevantly
increased fibre intake was usually not achieved [18].
Therefore, supplementation appears to be a more efficient
way to increase fibre consumption. Here, we hypothesised
that a continuous increase in fibre supplementation of ev-
eryday food intake would lead to a significant reduction
in the incidence of type 2 diabetes in a high-risk cohort.
In order to select and design foods containing effective
fibre types, and to estimate the effect size of increased
fibre intake, proof-of-principle studies are needed. We
therefore decided to perform a long-term prospective
randomised placebo-controlled trial investigating whether
insoluble cereal fibres would improve glucose metabolism
over 12 and 24 months in individuals with impaired glu-
cose tolerance (IGT).
Methods
Study populationMen and women with IGTwere recruited to
the Optimal Fibre Trial for Diabetes Prevention (OptiFiT) be-
tween March 2010 and October 2012, and enrolled at two
study sites (German Institute of Human Nutrition, Potsdam-
Rehbrücke, and Department of Endocrinology and Metabolic
Diseases, Charité University Medicine, Berlin). The partici-
pants were recruited via an existing database, public advertise-
ment, word of mouth, radio advertisements and flyers. A total
of 652 participants were screened using an OGTT, and 180
participants with IGT were enrolled into the study. IGT was
defined as a 2 h plasma glucose concentration of 7.8–
11.1 mmol/l.
According to the inclusion criteria, eligible study vol-
unteers were aged ≥18 years and were willing to partici-
pate in one of the two intervention groups over a period of
2 years. Exclusion criteria were a history of type 1 or type
2 diabetes, pregnancy, breastfeeding or plans to become
pregnant in the next 2 years, chronic or malignant dis-
eases, other wasting illnesses (e.g. severe cardiopulmo-
nary or autoimmune disorders), or a history or presence
of a significant psychiatric disorder, eating disorders,
medication with systemic corticosteroids, food allergies
or food intolerances that precludes a supplementation with
dietary fibre, and any other condition that would interfere
with participation in the study.
The study protocol was approved by the ethics committee
of the University of Potsdam as well as the ethics committee
of the Charité, and all individuals gave written informed con-
sent. The trial was registered at clinicaltrials.gov (NCT
01681173).
Study design OptiFiT is a randomised, placebo-controlled,
double-blind, parallel-group 24 month intervention study.
Volunteers were randomly assigned using a computer al-
gorithm to either placebo or fibre supplement by office
staff who were not involved in other study procedures.
Study enrolment was carried out by four study physicians,
and dietary intervention was conducted by the nutritionist.
Every 6 months, anthropometric data and serum markers
were assessed, and all participants repeated the OGTT after
12 and 24 months.
In addition to having the dietary supplement, all partic-
ipants started the 24 month study with a modified 1 year
lifestyle programme, based on PREvention of DIAbetes
Self-management (PREDIAS), a structured ‘Treatment
and Education Program for Prevention of type 2 diabetes’
[1, 19]. Within this course, the volunteers had group-
based consultations at regular intervals. During the second
year of the study, the participants continued receiving
their study supplement and were asked to continue regular
intake twice daily.
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Dietary intervention The 12 month lifestyle PREDIAS
consisted of 12 individual 2 h lessons divided into a core
intervention (eight lessons in 8 weeks) and booster ses-
sions (four lessons throughout the following 10 months)
[20]. With this cost-effective self-management approach,
participants should learn how to achieve a healthy bal-
anced diet and adequate physical activity. For our mod-
ified lifestyle intervention, participants completed food
records for 4 consecutive days, including 1 weekend
day, before the study and after 6, 12 and 24 months.
They were advised to record everything they ate and
drank, and the completeness of the food records was
checked with the study nutritionist. Nutrient intake was
determined using nutri t ion software PRODI 5.8
(Wissenschaftliche Verlagsgesellschaft, Stuttgart) based
on Bundeslebensmittelschlüssel 3.0 [21].
All participants were given detailed advice about how
to achieve the goals of the lifestyle intervention: an in-
crease in fibre intake to at least 15 g per 4200 kJ; a
reduction in weight of 5% or more (if baseline BMI
>25 kg/m2); a reduction in total intake of fat to less than
30% of energy consumed and of saturated fat to less than
10% of energy consumed; and moderate exercise for at
least 30 min per day. Frequent ingestion of whole-grain
products, legumes, vegetables, fruits, in particular berries,
low-fat milk and meat products, soft margarines, and veg-
etable oils rich in unsaturated fatty acids was recommend-
ed. At regular intervals, all participants received a pedom-
eter to assess their physical activity.
Dietary supplements The supplements were provided as
drinking powders every 6 months, when the individuals
attended the metabolic unit, and participants were
instructed to take the supplements twice daily. To enrich
the high-fibre supplement with insoluble cereal fibre, a
purified fibre extract derived from oat hulls was used,
which contained 70 wt% cellulose, 25 wt% hemicellulose
and 3–5 wt% lignin (Vitacel OF 560-30; Rettenmaier &
Söhne, Holzmuehle, Germany). Further details on the
supplement composition can be found elsewhere [8]. In
addition to this main component, the supplement
contained guar gum (1.92 wt%), isomaltulose, sucralose,
flavouring and dyes in small amounts. This supplement
added 15 g of mainly insoluble fibre per day (7.5 g per
serving) to the normal nutrition. The appearance of the
placebo supplement was comparable, but instead of the
high-fibre extract, a waxy maize starch with negligible
content of insoluble fibre and guar gum (0.8 g and 0.4 g
per serving, respectively) and isomaltulose was used.
The fibre and placebo supplements contained 251 and
276 kJ per serving, respectively, had a comparable fruity
taste and did not differ in appearance or texture. Blinding
applied to both participants and study personnel. The
volunteers were provided with instructions on how to
use the drinking powder: the recommended intake was
twice daily dissolved in 300 ml water, preferably before
breakfast and dinner. The participants received accurately
weighed quantities of the supplement in individual tins
and were asked to return the amount they did not con-
sume during their 6-monthly visits to the study unit.
Measurements and laboratory variables The primary outcome
was the change in 2 h post-challenge plasma glucose in the
annual 75 g OGTT after a 12 h fast. IGT and diabetes were
defined according to the recommendations of the ADA, IDF
and WHO: participants with IGT had plasma glucose levels
between 7.8 and 11.1 mmol/l, and a glucose value above that
range was an indicator of diabetes. If diabetes was diagnosed
during the study, the participants were referred to their general
physician for treatment, and follow-up in OptiFiT was
discontinued.
Blood samples for the OGTT were taken before and at
60, 120 and 180 min to measure glucose, insulin and C-
peptide. Capillary blood glucose concentrations were
measured immediately using the glucose oxidase method
(Super-GL glucose analyser; Dr Müller Gerätebau, Freital,
Germany); venous serum blood samples were analysed
batch-wise after storage (Horiba ABX Pentra 400,
Montpellier, France). Serum insulin and C-peptide were
measured using an ELISA technique (Mercodia,
Uppsala, Sweden).
In addition to the annual OGTT, routine laboratory
markers were measured every 6 months by standard
methods in the research laboratories of the German
Institute of Human Nutrition. After sampling in EDTA
or serum tubes, blood was immediately chilled on ice
and centrifuged, and aliquots were immediately frozen at
−80°C until assayed. Blood samples were analysed for
total cholesterol, LDL- and HDL-cholesterol, triacylglyc-
erols, NEFA, C-reactive protein, liver enzymes and HbA1c
levels (ABX Pentra 400; Horiba ABX).
The baseline and 6-monthly clinical examinations included
measurements of weight to the nearest 0.1 kg (in light indoor
clothes without shoes), height to the nearest 0.5 cm and waist
and hip circumference. Fat mass was assessed by bioelectrical
impedance analysis (BIA; Body Impedance Analyser
Quantum/S, Akern Bioresearch, Florence, Italy).
Calculations The AUC in response to the 75 g OGTT was
calculated for plasma glucose, insulin and C-peptide to
combine multiple readings into a single index by the trap-
ezoidal method. Insulin resistance was estimated by cal-
culating the following fasting indices: HOMA-IR [22],
QUICKI [23] and insulin sensitivity index of blood
NEFA [24]. Additionally, dynamic insulin sensitivity in-
dices—glucose effectiveness Sg [25] and the Cederholm
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index [26]—integrating plasma glucose and insulin con-
centrations during the OGTT, were used.
There is increasing evidence that hyperinsulinaemia in
the insulin-resistant state reflects two pathophysiological
processes: an increase in insulin secretion and a decrease
in hepatic insulin clearance (HIC) [27]. Based on the
OGTT data, HICC-peptide was calculated using the ratio of
incremental areas under the insulin and C-peptide curve:
HICC‐peptide ¼ AUCC‐peptide nmol=l½ =AUCInsulin pmol=l½ 
Statistical analyses The power calculation was based on an
estimated effect size of 0.39 mmol/l difference in 2 h OGTT
blood glucose levels (primary outcome) between the two
groups, an SD of 1.1 mmol/l and 80% power to detect the
effect. Such effects have recently been reported in other life-
style intervention studies [2, 19]. The estimated number of
participants to show these effects was 252, excluding a 25%
allowance for dropouts (n = 63).
Changes in fasting glucose, HbA1c, body weight, measures
of insulin sensitivity and insulin secretion, inflammation and
adipokines were defined as secondary outcomes.
To ensure uniform representation, calculations within
groups were performed assuming a non-normal distribution,
and thus differences in the variables studied before and after
the intervention within the groups were calculated by
Wilcoxon test. Using parametric tests whenever appropriate
did not lead to different overall results. For the comparison of
changes between groups, the unpaired Student’s t test with an
adjustment for change in body weight was used as far as data
normality was given. The characteristics of the participants are
presented as means ± SD. The results were considered signif-
icantly different if p ≤ 0.05. Every analysis was conducted
both as an intention-to-treat (last observation carried forward)
and as a per-protocol (completers only) analysis. If not explic-
itly stated, intention-to-treat and per-protocol analysis did not
lead to different results, and intention-to-treat data are
presented.
All statistical analyses were performed using SPSS for
Windows version 22.0 (SPSS, Chicago, IL, USA). The graphs
were created using GraphPad Prism version 6.0 (GraphPad
Software, San Diego, CA, USA).
Results
The study sample comprised 180 men and women with a
mean age of 60 ± 10 years. The baseline characteristics of
the two groups, including all measured risk factors for di-
abetes, were similar, except for sex distribution (Table 1),
which was not a matched variable for inclusion or
randomisation. A total of 136 participants completed the
first study year and were included in the primary analysis;
14 individuals were diagnosed with type 2 diabetes before
the 1 year visit, and 30 volunteers (17 from the fibre group)
dropped out for various reasons (illness, non-acceptance of
the supplement, lack of time).
Table 1 Characteristics of participants at study entry
Variable Placebo (n = 91) Fibre (n = 89)
Sex, n (%)
Male 37 (41%) 23 (26%)†
Female 54 (59%) 66 (74%)†







Type 2 diabetes 69.2 69.4
Type 1 diabetes 4.4 1.1
Blood pressure (mmHg)
Systolic 138 ± 17 140 ± 21
Diastolic 87 ± 11 90 ± 13
Weight (kg) 92.3 ± 20.7 88.1 ± 15.2
BMI (kg/m2) 33.0 ± 6.4 31.8 ± 5.3
Height (cm) 167 ± 9 167 ± 8
Hip circumference (cm) 114.0 ± 13.3 111.9 ± 12.2
Waist circumference (cm) 105.5 ± 14.4 103.5 ± 12.3
WHR 0.93 ± 0.1 0.93 ± 0.1
Body fat massa (%) 38.3 ± 9.1 37.0 ± 8.6
Fasting glucose (mmol/l) 6.0 ± 0.6 5.9 ± 0.7
2 h glucose (mmol/l) 9.2 ± 1.8 9.0 ± 1.7
HbA1c (mmol/mol) 38.0 ± 4.2 38.4 ± 4.2
HbA1c (%) 5.6 ± 0.4 5.7 ± 0.4
Insulin (pmol/l) 70.1 ± 38.2 62.5 ± 31.9
C-peptide (nmol/l) 0.57 ± 0.27 0.57 ± 0.33
HICC-peptide (pmol/nmol) 3.2 ± 1.3 3.1 ± 1.2
Total cholesterol (mmol/l) 5.6 ± 0.9 5.6 ± 1.1
HDL-cholesterol (mmol/l) 1.3 ± 0.3 1.2 ± 0.2
LDL-cholesterol (mmol/l) 3.5 ± 0.8 3.7 ± 0.9
CRP (nmol/l) 35.1 ± 37.1 45.0 ± 46.7
Aspartate aminotransferase (U/l) 28 ± 16 26 ± 7
Alanine aminotransferase (U/l) 33 ± 25 27 ± 11
γ-Glutamyl transferase(U/l) 31 ± 27 32 ± 31
Creatinine (μmol/l) 75.0 ± 16.1 78.5 ± 9.1
Uric acid (μmol/l) 341 ± 84 334 ± 77
Data are mean ± SD
aBody fat mass measured by BIA
Significant difference between the groups: † p ≤ 0.05
Diabetologia
During the 12months, mean bodyweight decreased by 2.0
± 5.2 kg in the fibre group and by 2.6 ± 5.2 kg in the placebo
group (total difference 0.6 ± 0.7 kg; not significant). Variables
such as BMI and waist and hip circumference significantly
decreased in both groups, fat mass (BIA) decreased in the
placebo group only, whereas blood pressure and WHR did
not change in either group (see electronic supplementary ma-
terial [ESM] Table 1).
The change in HbA1c levels was significantly different be-
tween the two groups (−0.2 ± 4.6 mmol/mol [−0.0 ± 0.0%; not
significant] vs +1.2 ± 5.2 mmol/mol [+0.1 ± 0.0%; not
significant]; total difference 1.4 ± 0.7 mmol/mol [0.1 +
0.0%]; p = 0.018, adjusted for weight change).
In the fibre and placebo group, respectively, we found sig-
nificantly decreased 2 h plasma glucose levels (−0.78 ±
1.88 mmol/l [p ≤ 0.001] vs −0.46 ± 1.80 mmol/l [p = 0.020];
total difference 0.32 ± 0.29 mmol/l; not significant) and AUC
for glucose (−71.4 ± 184.0 mmol/l × min [p ≤ 0.001] vs −59.4
± 156.7 mmol/l × min [p ≤ 0.001], total difference 12.0 +
27.0 mmol/l × min; not significant) without a significant dif-
ference between the groups. Fasting blood glucose did not
change (Fig. 1a–c).
Fig. 1 Glycaemic control after 1 year of intervention (placebo group,
n = 66; fibre group, n = 64). (a) Fasting glucose; (b) 2 h glucose; (c)
AUCGlucose; (d) fasting insulin sensitivity (HOMA-IR); (e) dynamic in-
sulin sensitivity (SICederholm); (f) HICC-peptide. White bars, placebo at
baseline; light grey bars, placebo after 1 year of intervention; dark grey
bars, fibre at baseline; black bars, fibre after 1 year of intervention. Data
are mean ± SD. Significant change within the group: *p ≤ 0.05, ***p ≤
0.001
Fig. 2 Glycaemic control in women after 1 year of intervention (pla-
cebo group, n = 34; fibre group, n = 47). (a) Fasting glucose; (b) 2 h
glucose; (c) AUCGlucose; (d) fasting insulin sensitivity (HOMA-IR); (e)
dynamic insulin sensitivity (SICederholm); (f) HICC-peptide. White bars,
placebo at baseline; light grey bars, placebo after 1 year of intervention;
dark grey bars, fibre at baseline; black bars, fibre after 1 year of interven-
tion. Data are mean ± SD. Significant change within the group: *p ≤ 0.05,
***p ≤ 0.001; significant change between groups: †p ≤ 0.05
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Fasting insulin levels significantly decreased only in the
fibre group (−9.1 ± 22.2 pmol/l [p = 0.001] vs −6.3 ±
29.9 pmol/l [p = 0.064]; total difference 2.8 ± 4.2 pmol/l
[p = 0.515]). The insulin response after the glucose load was
similar in the two groups. Additionally, 2 h C-peptide values
fell significantly in both groups (−0.2 ± 0.8 nmol/l [p = 0.018]
vs −0.3 ± 1.1 nmol/l [p = 0.045]), although the 3-h C-peptide
value was only significantly reduced in the fibre group (−0.2
± 0.6 nmol/l [p = 0.013] vs −0.1 ± 0.7 nmol/l [p = 0.504]).
Fasting indices such as HOMA-IR and dynamic indices,
combining insulin and glucose values during the OGTT, such
as glucose effectiveness (Sg; data not shown) and Cederholm
index, improved equally in the two groups (Fig. 1d, e). HIC
improved similarly in both groups (Fig. 1f).
Further secondary outcomes revealed significant changes in
C-reactive protein (CRP) (within both groups), IL-18 and
chemerin (placebo group only), and leucocyte count and leptin
(fibre group only), but the only significant difference between the
groups was for leucocyte count (see electronic supplementary
material [ESM] Table 1). During the first year of the intervention,
the change in AUCGlucose (r= 0.199, p = 0.114), HOMA-IR (r=
0.192, p= 0.125) and Cederholm index (r= −0.189, p = 0.135)
did not correlate with the weight change in the fibre group, but
showed significant correlations in the placebo group: AUCGlucose
(r = 0.250, p = 0.043), HOMA-IR (r = 0.284, p = 0.021) and
Cederholm index (r =−0.369, p = 0.002).
Analysis for interaction with sex did not reveal significant
results, but sex-specific analyses showed that, in women, only
the fibre group achieved significant changes in 2 h plasma
glucose (−0.88 ± 1.59 mmol/l [p ≤ 0.001] vs −0.22 ±
1.52 mmol/l [p = 0.311]), AUCGlucose (−65.4 ± 175.1 mmol/
l × min [p = 0.007] vs −28.8 ± 158.2 mmol/l × min [p =
0.242]), insulin levels (fasting, 2 h, 3 h and AUC; data not
shown) and HOMA-IR (−0.30 ± 1.04 [p = 0.034] vs −0.17 ±
1.06 [p = 0.261]). Of these, only the improvement in 2 h plas-
ma glucose levels was significantly different between the fibre
and placebo groups in women (total difference 0.67 ±
0.31 mmol/l; p = 0.015, adjusted for weight change; Fig. 2).
The relatively small and less balanced subgroup of men was
not analysed separately.
One of the main goals of the lifestyle intervention course
was a healthy high-fibre diet. The individual change in diet
was assessed using food records, and the evaluation showed
that, without the fibre supplement, the participants in both
groups were not able to increase their fibre intake (+0.9 ±
8.0 g vs +0.5 ± 7.0 g) despite advice to do so (Fig. 3).
However, the participants in the fibre-supplemented group
raised their average daily fibre intake from about
Fig. 3 Mean dietary fibre
intake without (a) and with (b)
supplementation. White bars,
placebo at baseline; light grey
bars, placebo after 1 year of
intervention; dark grey bars, fibre
at baseline; black bars, fibre after
1 year of intervention. Data are
mean ± SD. Significant change
within the group: ***p ≤ 0.001;
significant change between
groups: †††p ≤ 0.001
Table 2 Changes in dietary
habits during the first year of the
intervention
Variable Placebo (n = 59) Fibre (n = 58)
Baseline 12 months Baseline 12 months
Total energy intake (kJ/day) 8862 ± 2536 8205 ± 2339* 8795 ± 2059 7598 ± 1619***
Fat intake (g/day) 82 ± 28 71 ± 29* 80 ± 26 66 ± 22*
Protein intake (g/day) 84 ± 23 81 ± 22 81 ± 24 71 ± 20*
Carbohydrate intake (g/day) 225 ± 72 217 ± 56 225 ± 56 206 ± 44*
Total dietary fibre intake (g/day) 23 ± 8 23 ± 7 23 ± 7 22 ± 7
Insoluble 15 ± 5 15 ± 5 15 ± 5 15 ± 5
Soluble 7 ± 2 5 ± 4*** 7 ± 5 5 ± 3***
Alcohol (g/day) 9 ± 15 7 ± 11 10 ± 16 6 ± 8***
Data are mean ± SD
Nutrient intake was calculated from 4 day food records
Significant change within the group: *p ≤ 0.05, ***p ≤ 0.001. Individual variables did not differ significantly
between groups
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11.5 ± 9.3 g to 34.4 ± 8.3 g (p ≤ 0.001). The total energy intake
as well as the fat intake of the participants decreased during
the dietary intervention in both groups. In the fibre group, also
the mean protein and carbohydrate intake was significantly
lower after the first 12 months (Table 2).
After the second year of the study, 2 h plasma glucose
values were reduced in the fibre group by −0.48 ±
1.81 mmol/l (p = 0.020) and in the placebo group by
−0.22 ± 2.25 mmol/l (p = 0.366) compared with baseline
values (difference not significant). Surprisingly, the im-
provement in insulin sensitivity and HIC that could be
observed after 1 year remained, only slightly diminished,
in both groups after 2 years (Fig. 4), with no significant
difference between the groups.
During the 24month trial, diabetes was diagnosed in a total
of 25 individuals—16 in the placebo group and nine in the
fibre group (Table 3). Thus, the incidence of diabetes in the
fibre group was non-significantly 42–43% lower than in the
placebo group.
Discussion
The main finding of our study is a significantly stronger
reduction in HbA1c and 2 h glucose levels (in women) after
1 year of supplementation with insoluble dietary fibre in
individuals with IGT. Additionally, the incidence of diabe-
tes was 42% lower in the fibre group, although this did not
reach statistical significance. Although significant im-
provements in HbA1c and glucose levels did not persist
during the second year, the reduced incidence of diabetes
in the fibre group was maintained.
Prevention of diabetes by lifestyle intervention has been
investigated for several decades. Currently, the predominant
approach is based on weight loss and increased physical ac-
tivity. In these paradigms, dietary counselling includes low
dietary total and saturated fat consumption, reduced cholester-
ol intake and increased fibre intake. With these approaches,
recent lifestyle intervention programmes have been able to
reduce the incidence of diabetes by 40–60% [1, 2]. Their
counselling programmes were usually successful only with
regard to weight loss and physical activity, whereas goals for
fibre intake were achieved by as little as 25% of participants
[2, 15, 28]. Thus, improving the intake of dietary fibre is one
of the most taxing problems, as they are present in foods with
Fig. 4 Glycaemic control after 2 years of intervention (placebo group,
n = 54, fibre group, n = 52). (a) Fasting glucose; (b) 2 h glucose; (c)
AUCGlucose; (d) fasting insulin sensitivity (HOMA-IR); (e) dynamic in-
sulin sensitivity (SICederholm); (f) HICC-peptide. White bars, placebo at
baseline; light grey bars, placebo after 2 years of intervention; dark grey
bars, fibre at baseline; black bars, fibre after 2 years of intervention. Data
are mean ± SD. Significant change within the group: *p ≤ 0.05, ***p ≤
0.001
Table 3 Incidence of diabetes after the first and the second year
Variable Baseline 12 months 24 months
Placebo
NGT/IFG/IGT 91 (100) 61 (87.1) 48 (75.0)
Type 2 diabetes – 9 (12.9) 16 (25.0)*
Fibre
NGT/IFG/IGT 89 (100) 63 (92.6) 47 (83.9)
Type 2 diabetes – 5 (7.4) 9 (16.1)
p = 0.284a p = 0.230a
Data are n (%) of participants
Classification was according to capillary blood sugar level
a p values for the difference between the fibre and placebo group at the
given time point (significant if p ≤ 0.05)
*p ≤ 0.05, incident type 2 diabetes, placebo group, 24 months vs baseline
IFG, impaired fasting glucose; NGT, normal glucose tolerance
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high caloric density, such as whole-grain bread, or are poorly
accepted by participants due to taste (vegetables) or gastroin-
testinal side effects (grains and legumes).
Notably, the metabolic role of dietary fibre is controversial,
as only insoluble fibre has been shown in epidemiological
studies to be associated with a decreased risk of type 2 diabe-
tes [3, 5, 6, 29]. This is the first randomised intervention study
demonstrating an improvement in HbA1c over 1 year, a lower
incidence of diabetes over 2 years and significantly reduced
blood glucose levels upon intake of insoluble cereal fibre over
1 year in women. Similar studies have not been performed
with either insoluble or soluble fibre. Therefore, the impor-
tance of solubility and fermentability of dietary fibre and the
role of the microbiome in long-term improvements in blood
glucose levels requires targeted studies [7].
We found a similar improvement in HIC and HOMA-IR in
both groups. Weight loss tended to be slightly higher in the
placebo group (without a statistically significant difference
between the groups) and was almost non-existent at the end
of the study, thereby excluding the hypothesis that the ob-
served effects of insoluble cereal fibre were linked to weight
changes [29]. Also, metabolic improvements did correlate
with weight loss in the placebo group, but not in the fibre
group, supporting independence of antidiabetic fibre effects
from weight loss. These findings contradict recent studies
showing greater weight loss with high-fibre diets, especially
in individuals with impaired fasting glucose [30]. The meta-
bolic effects were more pronounced and significant in the
female subgroup, which may indicate sex-specific responses.
Alternatively, the male group might have been too small.
As a strength of our study, the control group received the
same lifestyle interventions known to improve glucose metab-
olism, but the significant effects of fibre supplementation
could nevertheless be demonstrated. Evaluating dietary com-
pliance, individuals in both groups were able to only slightly
increase their fibre intake by conventional dietary improve-
ments besides the supplement. Only 14.3% in the placebo
group and 11.2% in the fibre group were able to achieve an
average daily fibre load at the recommended level
(15 g/4200 kJ). When the supplement was included, 67.7%
of the fibre group participants managed to achieve the recom-
mendation. Therefore the significant additional improvement
in the cereal fibre group supports the use of insoluble fibres as
one component of diabetes prevention. In fact, insoluble fibres
are widely available byproducts of flour production and could
safely be added to numerous foods, thereby improving the
population’s cereal fibre intake. The absence of gastrointesti-
nal side effects is another positive characteristic of this type of
fibre, which underlines that fermentation is most likely not
necessary for the beneficial effects on glucose metabolism
[8, 29].
We experienced a dropout rate of 33%, with an even dis-
tribution between the two study groups, which is an excellent
outcome for a 2 year supplementation study and is comparable
to other lifestyle intervention studies [1, 2, 6, 16, 17].
Long-term observation after the end of dietary counselling
demonstrated that dietary patterns again deteriorated rapidly
and weight maintenance fell in most of the participants. Two-
hour glucose levels increased again in both study groups, al-
though supplementation was continued during the 1 year
follow-up period. We therefore conclude that a 1 year
follow-up after the end of dietary counselling was sufficient
to cover the main time frame of dietary rebound. Surprisingly,
insulin sensitivity and HIC remained similar to the year
before.
A placebo supplementation, especially in case of a study
focusing on fibre intake, is very hard to develop. We decided
to provide two supplements, which were equal in colour, di-
gestibility, taste and caloric content to assure blinding over the
entire study period and to avoid side effects by placebo or
fibre supplement. It was considered the best option to use
the slowly digestible carbohydrate isomaltulose as the main
component of the placebo drink.
Limitations of the present study need mentioning. First, as
is usual in most dietary trials, the sex distribution is skewed
towards women, leading to a relatively small male subgroup,
which then tends to be statistically unbalanced regarding body
weight and glycaemic variables. However, by analysing the
sexes separately, we were able to demonstrate that the pro-
nounced effect in terms of glycaemic improvement was sta-
tistically significant in the large female subgroup, which was
highly balanced regarding baseline anthropometric values.
Second, dietary compliance in terms of regular food intake
and supplementation was controlled by self-reporting ques-
tionnaires. No biomarker is available to validate the reported
fibre intake since alkylresorcinols (used to monitor cereal con-
sumption) are not generated from insoluble cereal fibre.
However, in general, we noticed an excellent correlation be-
tween reported energy intake and body weight changes, with
an even distribution and only a few under- and over-reporters.
We therefore assume that the dietary counselling was capable
of stimulating acceptable dietary documentation from most
volunteers.
Finally, there is no randomised control group, which would
allow a precise estimation of the cumulative incidence of dia-
betes if there were no intervention at all. However, previous
successful diabetes prevention trials have rendered the use of
control groups without intervention unethical.
In summary, we cannot clearly support major benefits from
a 2 year randomised placebo-controlled supplementation with
insoluble low-digestibility dietary fibre on glycaemic metab-
olism, as all predefined outcomes failed to reach statistical
significance. Effects on secondary outcomes, such as HbA1c
or AUCGlucose, were pronounced in the first year, particularly
in the more balanced female subgroup. Metabolic improve-
ments in 2 h glucose levels were connected to improved
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fasting insulin sensitivity, insulin secretion and HIC. Fasting
glucose levels did not change significantly.
Diabetes incidence was, non-significantly, 42–43% lower
in the fibre group over the entire study period. This effect size
is comparable with that of other lifestyle studies, which com-
pared dietary counselling with sham intervention. Dietary
counselling alone was not effective in increasing fibre intake
in a significant and relevant manner, which highlights the need
for fibre supplementation in order to achieve relevantly higher
cereal fibre intake.
Supplementation did not lead to relevant gastrointestinal
side effects, was accepted with moderate to high compliance
and was associated with dropout rates comparable with those
of other large lifestyle intervention studies with less intense
dietary treatment [1, 2]. Additionally, as a result of this, the
participants were unable to identify their treatment allocation
by self-observation of gastrointestinal side effects.
In modern developed societies, foods for which health
claims are made are often more expensive and consumed pre-
dominantly by people with a higher awareness of healthy eat-
ing. Thus, people with low income or lower educational levels
are not only at higher risk of becoming diabetic, but are also
less likely to eat healthy food. It therefore seems both plausi-
ble and useful not to advertise fibre as an especially healthy
component, but to supplement various types of food—cheap
and expensive, for snacks and for regular eating—with dietary
fibre.
Further studies are required to assess the need for and ef-
fectivity of supplementation with insoluble dietary fibre, as it
is well accepted owing to its low rate and intensity of side
effects and may still prove to be a promising way to decrease
the incidence of diabetes on a population level.
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